phosphorylcholine has been researched along with Malignant Melanoma in 8 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the response rate and toxicity of the alkylphosphocholine analogue, perifosine, in patients with metastatic or recurrent malignant melanoma." | 9.11 | Phase II study of perifosine in previously untreated patients with metastatic melanoma. ( Baetz, T; Belanger, K; Davis, M; Eisenhauer, E; Ernst, DS; Lohmann, R; Smylie, M; Wainman, N, 2005) |
| "To assess the response rate and toxicity of the alkylphosphocholine analogue, perifosine, in patients with metastatic or recurrent malignant melanoma." | 5.11 | Phase II study of perifosine in previously untreated patients with metastatic melanoma. ( Baetz, T; Belanger, K; Davis, M; Eisenhauer, E; Ernst, DS; Lohmann, R; Smylie, M; Wainman, N, 2005) |
| "We investigated PC3 prostate cancer, MCF-7 breast cancer and A375 melanoma cells, and determined that, consistent with previous studies, MRS-detectable levels of phosphocholine decreased significantly in all cell lines (to 63%, 50% and 18% of the control, respectively) following MEK inhibition with U0126." | 1.40 | MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition. ( Lodi, A; Ronen, SM; Woods, SM, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, S | 2 |
| Xie, X | 1 |
| Wang, W | 1 |
| Jiang, S | 2 |
| Mei, W | 2 |
| Zhang, Y | 1 |
| Liu, S | 2 |
| Yu, X | 2 |
| Wang, X | 1 |
| Yan, X | 1 |
| Pegoraro, C | 1 |
| Cecchin, D | 1 |
| Gracia, LS | 1 |
| Warren, N | 1 |
| Madsen, J | 1 |
| Armes, SP | 1 |
| Lewis, A | 1 |
| Macneil, S | 1 |
| Battaglia, G | 1 |
| Lodi, A | 1 |
| Woods, SM | 1 |
| Ronen, SM | 1 |
| Teymouri, M | 1 |
| Farzaneh, H | 1 |
| Badiee, A | 1 |
| Golmohammadzadeh, S | 1 |
| Sadri, K | 1 |
| Jaafari, MR | 1 |
| Ernst, DS | 1 |
| Eisenhauer, E | 1 |
| Wainman, N | 1 |
| Davis, M | 1 |
| Lohmann, R | 1 |
| Baetz, T | 1 |
| Belanger, K | 1 |
| Smylie, M | 1 |
| Ragnarsson-Olding, B | 1 |
| Djureen-Mårtensson, E | 1 |
| Månsson-Brahme, E | 1 |
| Hansson, J | 1 |
| Barna, BP | 1 |
| James, K | 1 |
| Deodhar, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study Of Perifosine (D-21266) In Previously Untreated Patients With Metastatic Or Recurrent Malignant Melanoma[NCT00053781] | Phase 2 | 18 participants (Actual) | Interventional | 2003-06-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for phosphorylcholine and Malignant Melanoma
| Article | Year |
|---|---|
Phase II study of perifosine in previously untreated patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Arthralgia; Chondrocalcinosis; Female; Humans; Liver Neoplasms; Lung | 2005 |
7 other studies available for phosphorylcholine and Malignant Melanoma
| Article | Year |
|---|---|
Choline phosphate lipid as an intra-crosslinker in liposomes for drug and antibody delivery under guard.
Topics: Animals; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Lipids; Liposomes; Melanoma; Mice; Ph | 2022 |
Choline phosphate lipid insertion and rigidification of cell membranes for targeted cancer chemo-immunotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Doxorubicin; Drug Delivery Systems; | 2021 |
Enhanced drug delivery to melanoma cells using PMPC-PDPA polymersomes.
Topics: Antibiotics, Antineoplastic; Cell Membrane Permeability; Cells, Cultured; Doxorubicin; Drug Delivery | 2013 |
MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition.
Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Butadienes; Cell Line, Tumor; Glycolysis; Humans; M | 2014 |
Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Doxorubicin; Drug Delivery Syst | 2015 |
Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Melanoma; Neo | 2005 |
Activation of human monocyte tumoricidal activity by C-reactive protein.
Topics: Astrocytes; Astrocytoma; C-Reactive Protein; Carcinoma, Renal Cell; Cell Line; Cytotoxicity Tests, I | 1987 |